Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Heparin Stories

2010-07-01 07:00:00

SCHAUMBURG, Ill., July 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's nine presentations of heparin sodium injection, USP. Heparin is a vital anticoagulant, preventing the formation of clots and extension of existing clots within the blood, routinely used in surgical and dialysis settings. According to IMS, 2009 U.S. sales of all forms of...

2010-06-20 08:43:26

Research harnesses enzyme's anti-blood clotting abilities In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S. "Thrombosis is one of the most prevalent causes of fatal disease,"...

2010-06-18 12:54:00

ST. LOUIS, June 18 /PRNewswire-USNewswire/ -- In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S. "Thrombosis is one of the most prevalent causes of fatal disease," said...

2010-06-14 18:33:00

SUNNYVALE, Calif., June 14 /PRNewswire/ -- Cardiva Medical, Inc. announced today that Charles Maroney has been appointed President, Chief Executive Officer and member of the Cardiva Board of Directors effective immediately. Mr. Maroney succeeds Rick Anderson, who has served as interim CEO since March 2, 2010 and who will remain in his role as Chairman of the Board. Cardiva also announced the completion of a financing that is directed to bring the company's next generation product to...

2010-06-01 19:28:01

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells. Malaria is an infection of red blood cells that is transmitted by mosquitoes. The most common form of malaria is caused by the parasite Plasmodium falciparum which burrows into red blood cells where it rapidly multiplies, leading to massive numbers of parasites in the blood stream that can...

2010-05-25 08:05:00

PHILADELPHIA, May 25 /PRNewswire/ -- Lyophilized heparin, a proprietary anticoagulant developed specifically for cord blood collection, demonstrated a better ability to preserve the number of viable cells over a longer period of time than a commonly-used anticoagulant, citrate phosphate dextrose (CPD), according to a study presented today at the International Society for Cellular Therapy (ISCT) Annual Meeting. (Logo: http://www.newscom.com/cgi-bin/prnh/20090326/SF89756LOGO) "Clinical...

2010-03-10 09:53:00

WASHINGTON, March 10 /PRNewswire-USNewswire/ -- Allan Coukell, director of the Pew Prescription Project, issued the following statement today, commenting on a hearing at the U.S. House Energy and Commerce Subcommittee on Health, where Food and Drug Administration (FDA) Principal Deputy Commissioner Joshua M. Sharfstein is expected to present testimony regarding the agency's ability to protect Americans from unsafe drugs made overseas: "Two years after dozens of Americans lost their lives...

2010-03-02 19:00:00

SUNNYVALE, Calif., March 2 /PRNewswire/ -- Cardiva Medical, Inc. announced today that Founder and CEO Augustine Lien has resigned effective March 5. The company's Board of Directors has appointed Rick Anderson, appointed Chairman of the Board in October 2009, to serve as interim CEO. Mr. Lien will remain a member of the Board of Directors. Mr. Lien founded Cardiva in 2003 and then has led the company for the past 7 years as Chairman and CEO. During that time, Cardiva has launched three...

2010-02-10 07:30:00

SOUTH SAN FRANCISCO, Calif., Feb. 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that results from its Phase 2 EXPLORE-Xa clinical trial of betrixaban, an investigational oral direct Factor Xa inhibitor anticoagulant, will be presented during a late-breaking results session at the American College of Cardiology's (ACC) 59th Annual Scientific Session in Atlanta in March. EXPLORE-Xa is a Phase 2 dose-ranging trial evaluating betrixaban for stroke prevention in 500 patients...

2009-12-07 07:00:00

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new...